Oligonucleotide drug slows Alzheimer’s decline across every dose tested in Phase 2 and reframes the field’s central therapeutic target. #longevity# #geroscience# #Alzheimers# #oligonucleotide# #Phase2#

⚡ 𝐔𝐏𝐃𝐀𝐓𝐄: $LLY Eli Lilly Breaks Ground on $𝟲.𝟱 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 Houston Manufacturing Facility 👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ➤ 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 breaks ground on $𝟲.𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 Houston manufacturing facility. ➤ Site will manufacture APIs for 𝗙𝗼𝘂𝗻𝗱𝗮𝘆𝗼 (𝗼𝗿𝗳𝗼𝗿𝗴𝗹𝗶𝗽𝗿𝗼𝗻) and other medicines. ➤ Foundayo is Lilly's first synthetic oral 𝗚𝗟𝗣-𝟭 medicine. ➤ Facility supports Lilly's $𝟱𝟬 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 U.S. manufacturing expansion. ➤ Houston facility will create over 𝟲𝟬𝟬 high-wage jobs. ➤ Construction is expected to support approximately 𝟰,𝟬𝟬𝟬 jobs. ➤ Lilly commits $𝟭𝟮.𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 toward workforce development with San Jacinto College. ➤ Site will also manufacture advanced therapeutics, including 𝗼𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲𝘀. ➤ Facility will deploy 𝗔𝗜, machine learning, automation, and advanced analytics. ➤ Foundayo's full global rollout is targeted for 𝟮𝟬𝟮𝟳. 👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: ➤ Expands domestic capacity for Lilly's growing 𝗚𝗟𝗣-𝟭 medicine portfolio. ➤ Strengthens Lilly's U.S. supply chain for critical pharmaceutical ingredients. ➤ Adds manufacturing capacity supporting potential international Foundayo expansion. ➤ Creates skilled manufacturing jobs while developing Houston's biopharmaceutical workforce. ➤ Advances Lilly's broader $𝟱𝟬 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 U.S. reshoring strategy. 👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: 𝗗𝗮𝘃𝗶𝗱 𝗔. 𝗥𝗶𝗰𝗸𝘀, Lilly Chair and CEO: "We are thrilled to break ground on our latest 'medicines made in America' site in the great state of Texas. This $6.5B investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly's latest products from Texas to people here at home and around the world." 𝗘𝗱𝗴𝗮𝗿𝗱𝗼 𝗛𝗲𝗿𝗻𝗮𝗻𝗱𝗲𝘇, Executive Vice President and President of Lilly Manufacturing Operations: "When you invest in a place like Houston, you invest in its people first. This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home. The facility itself is being built to the highest standards for safety, quality and responsible stewardship of the environment, and every one of these jobs helps bring innovative medicines to the patients counting on them." 𝗚𝗿𝗲𝗴 𝗔𝗯𝗯𝗼𝘁𝘁, Texas Governor: "Texas is the global hub for life sciences. This $6.5 billion Lilly investment in Houston is the largest active pharmaceutical ingredient project in Texas history and will create more than 600 high-wage jobs, right here in Texas. Texas will produce these medicines at home so we can deliver life-changing treatments to millions of Americans." 𝗗𝗿. 𝗕𝗿𝗲𝗻𝗱𝗮 𝗛𝗲𝗹𝗹𝘆𝗲𝗿, Chancellor of San Jacinto College: "Eli Lilly's manufacturing investment in Generation Park is a tremendous opportunity for the Houston region. San Jacinto College is proud to work with Lilly to develop the skilled workforce needed to support the growth of biopharmaceutical manufacturing. Together, we will expand industry-informed education and hands-on training pathways that prepare students and incumbent workers with the technical skills these advanced manufacturing careers require. This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region."